<DOC>
	<DOCNO>NCT00006512</DOCNO>
	<brief_summary>To identify predispose gene responsible asthma bronchial hyperresponsiveness ( BHR ) region 5p13.3 inbred Hutterite community .</brief_summary>
	<brief_title>Characterizing 5P-Linked BHR Susceptibility Locus</brief_title>
	<detailed_description>BACKGROUND : Asthma common chronic disease industrialize nation , affect than10 million people U.S. alone . Familial aggregation concordance rate monozygotic twin suggest genetic component asthma . Dr. Ober colleague conduct study genetics asthma atopy Hutterites , inbred population European origin practice communal lifestyle . A genome-wide screen 564 marker ( average space 6 cM ) complete extended pedigree 717 Hutterites well characterize respect asthma , atopy , related phenotype . These individual descendant 64 ancestor live early 1700 's early 1800 's . Evidence linkage bronchial hyperresponsiveness ( BHR ) likelihood ratio test extend 30 centimorgans ( cM ) chromosome 5p , P-values small 0.001 . Additional evidence linkage location evident transmission disequilibrium test ( P=0.0061 ) . Typing additional marker region identify critical region 2.4 cM , correspond 1.5 Mb DNA , high risk haplotype transmit affected individual . The study conduct response Request Applications , `` Positional Candidate Approaches Asthma Gene Discovery '' release Ocatober , 1999 . DESIGN NARRATIVE : Dr. Ober colleague characterize 5p-linked BHR susceptibility locus inbred Hutterites positional cloning replicate finding outbred , ethnically diverse population . They examine single nucleotide polymorphism ( SNPs ) space 10 kb apart gene , assess evidence transmission affect offspring SNP SNP haplotype . Associations Hutterites replicate two outbred sample ( Caucasian sample Germany , African American sample Chicago ) . The functional effect associate variant assess vitro assay well genotype-phenotype study outbred sample evaluate asthma atopy phenotype . Identifying asthma BHR susceptibility locus may identify novel pathway asthma pathogenesis , thereby allow development new therapy intervention strategy common disease .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>